E-Newsletter - December 2020


The Alliance for Clinical Trials in Oncology and Alliance Foundation Trials, LLC presented an array of novel data from many of its hematology studies during the virtually-held 62nd American Society of Hematology (ASH) Annual Meeting and Exposition December 5-8. Many of these data will help change the delivery of hematologic cancer care or help elucidate the underlying cause and effect relationships seen in this field.

Here's a snapshot of Alliance and AFT abstracts, along with a few others of interest.
Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance)
Abstract #: 6
Lead author: Bhavana Bhatnagar

Clinical and Prognostic Implications of PTPN11 Mutations in Acute Myeloid Leukemia (Alliance)
Abstract #: 1069
Lead author: Sydney Fobare
Molecular Landscape and Prognostic Impact of FLT3 Internal Tandem Duplication Insertion Site in Acute Myeloid Leukemia (AML): Results from the Ratify Study (Alliance 10603)
Abstract #: 391
Lead author: Frank Rücker
Local Review Versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial [Alliance]
Abstract #: 1195
Lead author: Amy Ruppert
A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia
Abstract #: 3482
Lead author: Matthew C. Cheung
Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of Griffin
Abstract #: 3243
Lead author: Peter M. Voorhees
Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
Abstract #: 549
Lead author: Jonathan L. Kaufman
Of Special Note
SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Abstract #: 2969
Lead author: Alex F. Herrera
This clinical trial - S1826, led by SWOG Cancer Research Network - represents the largest advanced-stage Hodgkin lymphoma (HL) study in the history of the North American cooperative groups and the first prospective collaboration between the Children's Oncology Group and the adult cooperative groups, including SWOG, ECOG-ACRIN, Alliance, and the Canadian Cancer Trials Group, in HL.

Data from Alliance Trials
Meta-Analysis of Genome-Wide Association Studies of Acute Myeloid Leukemia (AML) Patients Identifies Variants Associated with Risk of 11q23/KMT2A-Translocated and Core-Binding Factor (CBF) AML and Suggests a Role for Transcription Elongation in Leukemogenesis
Abstract #: 1983
Lead author: Christopher J. Walker
Differential Impact of Prognostically Significant Gene Mutations in Acute Myeloid Leukemia (AML) Patients (Pts) Older Than 70 Years (y) Treated with Cytarabine-Based Induction Therapy
Abstract #: 2895
Lead author: Marius Bill



For other articles in this issue of the Alliance E-News newsletter, see below.